SOPHiA GENETICS (NASDAQ:SOPH) Chairman Sells 20,000 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $6.92, for a total transaction of $138,400.00. Following the completion of the sale, the chairman owned 3,472,822 shares of the company’s stock, valued at $24,031,928.24. The trade was a 0.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.63, for a total transaction of $132,600.00.
• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.29, for a total transaction of $153,356.49.
• On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.62, for a total transaction of $47,770.00.
• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.28, for a total transaction of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.25, for a total transaction of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total transaction of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.80, for a total value of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.24, for a total value of $44,540.00.

SOPHiA GENETICS Trading Down 7.9%

SOPH traded down $0.54 during mid-day trading on Wednesday, reaching $6.30. The stock had a trading volume of 721,997 shares, compared to its average volume of 214,122. The stock has a market capitalization of $528.51 million, a P/E ratio of -12.12 and a beta of 0.96. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The firm’s fifty day simple moving average is $5.52 and its two-hundred day simple moving average is $5.11. SOPHiA GENETICS SA has a 52 week low of $2.96 and a 52 week high of $7.21.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The firm had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. On average, equities analysts predict that SOPHiA GENETICS SA will post -0.58 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Hennion & Walsh Asset Management Inc. bought a new position in shares of SOPHiA GENETICS in the 2nd quarter worth $567,000. Royal Bank of Canada grew its stake in shares of SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after purchasing an additional 18,781 shares during the period. Sei Investments Co. bought a new stake in SOPHiA GENETICS in the first quarter valued at about $1,772,000. Principal Financial Group Inc. increased its holdings in SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares during the last quarter. Finally, Hodges Capital Management Inc. bought a new stake in SOPHiA GENETICS in the first quarter valued at about $2,157,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

SOPHiA GENETICS News Summary

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: AstraZeneca collaboration: SOPHiA GENETICS entered a multiyear global agreement with AstraZeneca to develop, validate and commercialize two companion diagnostics for precision-oncology therapies. The deal could expand SOPH’s role in pharmaceutical clinical development and create longer-term commercial opportunities. SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
• Positive Sentiment: Higher full-year outlook: Management raised 2026 revenue guidance to $94 million-$96 million, representing 22%-24% year-over-year growth and exceeding the roughly $93.4 million consensus estimate. The company is also targeting adjusted EBITDA breakeven by year-end. SOPHiA GENETICS Outlines 2026 Revenue Outlook
• Positive Sentiment: Revenue and analyst support: Second-quarter revenue increased 27% year over year to $23.3 million, surpassing the $21.7 million consensus estimate. Adjusted EBITDA losses improved 27% year over year to $8.8 million. HC Wainwright raised its price target from $12 to $14 and BTIG lifted its target from $8 to $9; both firms maintained Buy ratings.
• Negative Sentiment: EPS miss and ongoing losses: SOPHiA GENETICS reported a quarterly loss of $0.26 per share, missing the $0.21 consensus loss estimate. Net loss remained $22.4 million, while reported gross margin declined to 64.6% from 67.0% a year earlier. These results may be driving caution despite the improved revenue outlook. SOPHiA GENETICS Reports Second Quarter 2026 Results

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. HC Wainwright raised their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday. BTIG Research lifted their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.